Analysis of binding affinities for celecoxib analogues with COX-1 and COX-2 from combined docking and Monte Carlo simulations and insight into the COX-2/COX-1 selectivity

被引:130
|
作者
Price, MLP [1 ]
Jorgensen, WL [1 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
关键词
D O I
10.1021/ja001018c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The origins of binding affinity and COX-2/COX-1 selectivity for analogues of celecoxib have been explored using an approach that combines docking with Monte Carlo (MC) simulations. These inhibitors are COX-2-selective nonsteroidal antiinflammatory drugs (NSAIDs) that are of current interest because the gastrointestinal irritation they cause is reduced compared to that caused by traditional NSAIDs. We report a novel docking method, based on a combined Tabu and Monte Carlo protocol, that determines starting conformations for MC simulations. Using the docking-predicted starting conformations, relative changes in binding free energies were computed for methyl, ethyl, hydroxymethyl, hydroxyl, thiomethyl, methoxy, trifluoromethyl, chloro, fluoro, and unsubstituted derivatives with the MC free energy perturbation (FEP) method. The computed free energies are in good accord with IC50 values, and the structural information from the simulations can be used to explain the experimentally observed binding trends. In addition, the docking and FEP results have provided clarification of the binding conformation of the phenylsulfonamide moiety and the origin of COX-2/COX-1 selectivity. Namely, the COX-2 Val --> COX-1 Ile subtitution is accompanied by an unfavorable conformational shift of the phenylsulfonamide ring.
引用
收藏
页码:9455 / 9466
页数:12
相关论文
共 50 条
  • [31] Bioactivation is essential for inhibition of COX-1 and COX-2 activity by aceclofenac
    Hinz, B
    Rau, T
    Auge, D
    Werner, U
    Ramer, R
    Rietbrock, S
    Brune, K
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2003, 367 : R114 - R114
  • [32] 对COX-1和COX-2的再认识
    施桂英
    中华风湿病学杂志, 2000, (04) : 197 - 198
  • [33] COX-1 and COX-2 expression in osteosarcoma and benign bone tumors
    Gonlusen, Gulfiliz
    Erer, Aysen
    Ergin, Melek
    Erdogan, Seyda
    Ozbarlas, Serdar
    VIRCHOWS ARCHIV, 2007, 451 (02) : 578 - 578
  • [34] Immunoexpression of COX-1 and COX-2 in inflammatory bowel disease (IBD)
    Franco, Marcello
    Ribeiro Paiotti, Ana Paula
    Romero, Monica F. S.
    Neto, Ricardo Artigiani
    Oshima, Celina Tizuko F.
    MODERN PATHOLOGY, 2006, 19 : 58 - 58
  • [35] Select Dietary Phytochemicals Function as Inhibitors of COX-1 but Not COX-2
    Li, Haitao
    Zhu, Feng
    Sun, Yanwen
    Li, Bing
    Oi, Naomi
    Chen, Hanyong
    Lubet, Ronald A.
    Bode, Ann M.
    Dong, Zigang
    PLOS ONE, 2013, 8 (10):
  • [36] Expression of COX-1 and COX-2 in a clinical model of acute inflammation
    Khan, Asma A.
    Iadarola, Michael
    Yang, Hslu-Ying T.
    Dionne, Raymond A.
    JOURNAL OF PAIN, 2007, 8 (04): : 349 - 354
  • [37] Localization of COX-1 and COX-2 in the intracranial dura mater of the rat
    Zhang, Xi-Chun
    Kainz, Vanessa
    Jakubowski, Moshe
    Burstein, Rarni
    Strassman, Andrew
    Levy, Dan
    NEUROSCIENCE LETTERS, 2009, 452 (01) : 33 - 36
  • [38] Differential expression of COX-1 and COX-2 in the gastrointestinal tract of the rat
    Haworth, R
    Oakley, K
    McCormack, N
    Pilling, A
    TOXICOLOGIC PATHOLOGY, 2005, 33 (02) : 239 - 245
  • [39] Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis
    Roca-Ferrer, J.
    Pujols, L.
    Gartner, S.
    Moreno, A.
    Pumarola, F.
    Mullol, J.
    Cobos, N.
    Picado, C.
    THORAX, 2006, 61 (07) : 592 - 596
  • [40] COX-1, COX-2 inhibitors and antifungal agents from Croton hutchinsonianus
    Athikomkulchai, S
    Prawat, H
    Thasana, N
    Ruangrungsi, N
    Ruchirawat, S
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2006, 54 (02) : 262 - 264